Home » Topics » Disease categories and therapies » Urology

Urology
RSS

Potent and selective PDE5 inhibitor may be useful in erectile dysfunction, heart failure

March 27, 2000

Pharmacokinetics, efficacy and safety of PNU-83757 examined in patients with ED

March 23, 2000

ASCPT news: pharmacodynamics of VPA-985 + hydrochlorothiazide in humans

March 21, 2000

Novel class of human 5alpha-reductase inhibitors undergoes evaluation at Yamanouchi

March 21, 2000

Abbott's new alpha1A-adrenoceptor agonists, their preparation, activity and use

March 20, 2000

Synsorb Pk receives fast track designation from FDA for prevention of HUS

March 20, 2000

Clinical trials of (S)-doxazosin in BPH commenced

March 15, 2000

Detrusitol available in Spain for hyperactive bladder

March 14, 2000

Novel dihydropyrimidines from Merck are potent and selective alpha1A-adrenoceptor antagonists

March 14, 2000

Pharmacia & Upjohn submits applications for once-daily Detrol formulation

March 10, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal
BioWorld
Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui...
Unique trial strategy muddies the ODAC waters for camizestrant
BioWorld
Following a discussion that focused more on a new personalized trial strategy rather than the proposed therapy, the U.S. FDA’s Oncologic Drugs Advisory Committee...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...